45 Results for "

MIAPaCa-2

" in MedChemExpress (MCE) Product Catalog:
Products (45)

45 Results for "MIAPaCa-2" in MCE Product Catalog:

Cat. No.: HY-172177
Target:  

Apoptosis HDAC ROCK

Research Areas:  

Cancer

ROCK/HDAC-IN-2 (Compound C-9) is a ROCK/HDAC inhibitor, with IC50 values of 0.185 µM, 0.8 µM, and 0.7 µM for HDAC6, ROCK1, and ROCK2, respectively. ROCK/HDAC-IN-2 can induce apoptosis and changes in mitochondrial membrane potential in cancer cells, demonstrating significant antitumor activity. ROCK/HDAC-IN-2 can be used in the research of pancreatic ductal adenocarcinoma (PDAC) and triple-negative breast cancer (TNBC) .
loading...
    loading...
Cat. No.: HY-16232R
CAS No.: 132682-98-5
Synonyms: D 19575 (Standard); Glucosylifosfamide mustard (Standard)
Research Areas:  

Cancer

Glufosfamide (Standard) is the analytical standard of Glufosfamide. This product is intended for research and analytical applications. Glufosfamide is a glucose-conjugated alkylating cytotoxic agent and a derivative of Ifosfamide (HY-17419). Glufosfamide induces apoptosis frequency and increase the expression of caspase-9 and caspase-3 in cancer cells. Glufosfamide shows great anti-tumor activity in MiaPaCa-2-RFP mouse model. Glufosfamide can be used for the study of hepatocellular carcinoma, prostate cancer and pancreatic carcinoma [2] .
loading...
    loading...
Cat. No.: HY-184191
CAS No.: 1185003-32-0
Research Areas:  

Cancer

PGK1-IN-3 is an orally active PGK1 inhibitor with human PGK1 IC50 values of 0.48 μM and human PGK1 Kd of 63 nM. PGK1-IN-3 binds to the ADP-binding pocket of PGK1, inhibits glycolysis, and reduces glucose consumption and lactate production. PGK1-IN-3 can be used for the research of pancreatic cancer .
loading...
    loading...
Cat. No.: HY-118598
CAS No.: 17511-50-1
Target:  

Autophagy

Research Areas:  

Cancer

UA8967 is a membrane-active antitumor agent. UA8967 exhibits enhanced cytotoxicity against cancer cells harboring a deletion of the tumor suppressor gene DPC4. By disrupting the integrity of the cytoplasmic membrane, UA8967 triggers early caspase-independent autophagy and ultimately leads to non-apoptotic cell lytic death. UA8967 can be used in research on colon cancer and pancreatic cancer .
loading...
    loading...
Cat. No.: HY-181529
CAS No.: 1212623-02-3
Target:  

VDAC PERK

Research Areas:  

Cancer

NCATS-SM0225 is an endoplasmic reticulum-associated degradation (ERAD) inhibitor and a direct binder of VDAC1, VDAC2 and VDAC3. NCATS-SM0225 exhibits an IC50of 1.02 μM for ERAD and a Kd of 3.13 μM for human VDAC1 binding. NCATS-SM0225 disrupts cellular calcium homeostasis, enhances VDAC1-IP3R coupling and activating PERK. NCATS-SM0225 selectively kills cancer cells, exhibits tumor growth inhibitory effects in melanoma xenograft models. NCATS-SM0225 can be used for research on multiple cancers including melanoma, as well as the molecular mechanisms of ERAD and calcium homeostasis regulation .
loading...
    loading...